Financial Personal
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s AD2C for precision oncology solutions BEIJING & ALAMEDA, Calif. & TAIPEI — Biocytogen (HKEX: 0231
BEIJING & ALAMEDA, Calif. & TAIPEI -- Biocytogen (HKEX: 02315) and Acepodia (6976:TT), today announced a groundbreaking strategic partnership to jointly assess a dual-payload bispecific antibody-drug conjugate (BsAD2C) program. Read More
